BioCentury | Jun 16, 2020
Finance

Barcelona’s Ona takes aim at metastasis with €30M series A

...pathway whose inhibition has been associated with prevention of metastasis. Barcelona-based Asabys Partners, which was Ona Therapeutics’...
...the high cost of Phase III trials could drive that decision, she said. Paul Bonanos, Associate Editor Ona Therapeutics CD36...
Items per page:
1 - 1 of 1
BioCentury | Jun 16, 2020
Finance

Barcelona’s Ona takes aim at metastasis with €30M series A

...pathway whose inhibition has been associated with prevention of metastasis. Barcelona-based Asabys Partners, which was Ona Therapeutics’...
...the high cost of Phase III trials could drive that decision, she said. Paul Bonanos, Associate Editor Ona Therapeutics CD36...
Items per page:
1 - 1 of 1